eli lilly hims - Search News

Hims & Hers Health, Eli Lilly

Seeking Alpha · 3h

Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges. Find out who is the winner.

Reuters on MSN · 1d

Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform (April 1)

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug Zepbound and diabetes medicine Mounjaro — and generics of Novo's diabetes drug,

Fierce Healthcare · 6h

DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss platform.

Physician's Weekly15h

Zepbound Now Available Through Hims AND Hers

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

9h

‘Hold the Phone,’ Says Morgan Stanley on Hims & Hers Health Stock (HIMS)

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

2d

Eli Lilly is coming after makers of copycat versions of Zepbound

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results